Gene therapy by cell specific targeting
US6982082B1 · kind B1 · utility
8Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 27, 1997 |
| Grant date | Jan 3, 2006 |
| Priority date | — |
| Expiry date | Aug 27, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.